SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S56 - Movement Disorders: Huntington's Disease and Drug-Induced Dyskinesias

Event Time: Friday April 28, 2017 3:30 pm to 5:30 pm
Topic(s): Movement Disorders
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
5:05 PM - 5:30 PM Discussion Alan Diamond DO 

Disclosures

Speaker Disclosure
Alan Lee Diamond, DO Dr. Diamond has nothing to disclose.

Abstract Presenters

Start Time Pub. Title Presenter
3:30 PM 001 Selectivity and Biodistribution of WVE-120101, a Potential Antisense Oligonucleotide Therapy for the Treatment of Huntington′s Disease Meena M
Disclosure:
Dr. Vargeese has received personal compensation for activities with WAVE Life Sciences as an employee.

3:42 PM 002 Huntingtin As a Scaffold for Selective Macroautophagy Erin Furr-Stimming, MD
Disclosure:
Dr. Zhang has nothing to disclose.

3:54 PM 003 Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results Rajesh Pahwa, MD, FAAN
Disclosure:
Dr. Pahwa has received consulting fees from Abbvie, ACADIA, Acorda, Adamas, Cynapses, Global Kinetics, Lundbeck, Neurocrine, Pfizer, Sage, Sunovion, Teva Neuroscience and US World Meds.. As the Co-Editor-In-Chief of the International Journal of Neuroscience.. Research funds awarded to the University of Kansas Medical Center from Abbvie, Adamas, Avid, Biotie, Boston Scientific, Civitas, Cynapses, Kyowa, National Parkinson Foundation, NIH/NINDS, Parkinson Study Group, Pfizer..

4:06 PM 004 Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change (CGIC) with Deutetrabenazine Treatment in Moderate to Severe Tardive Dyskinesia (TD) Hubert H. Fernandez, MD, FAAN
Disclosure:
Dr. Fernandez has received honoraria from Prime Education Inc, Carling Communications, Medscape, as a speaker in CME events. Dr. Fernandez has received honoraria from Biogen, GE Health Care, Lundbeck, Merz Pharmaceuticals and Pfizer Pharmaceuticals, as a consultant.. Dr. Fernandez has received a stipend from International Parkinson and Movement Disorders Society for serving as Medical Editor of the MDS Web Site. . Dr. Fernandez has received royalty payments from Demos Publishing for serving as a book author/editor. Dr. Fernandez has received research support from Abbvie, Acadia, Auspex/Teva, Biotie/Acorda Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Rhythm, Synosia, but has no owner interest in any pharmaceutical company. NIH/NINDS, Parkinson Study Group, Rhythm, Synosia, Teva, but has no owner interest in any pharmaceutical company. .

4:18 PM 005 Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension) Stewart Factor, DO, FAAN
Disclosure:
Dr. Factor has nothing to disclose.

4:30 PM 006 Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Effect of Fixed-Dose Deutetrabenazine by Baseline Comorbidities Karen E. Anderson
Disclosure:
Dr. Anderson has received personal compensation for activities with LEGATO-HD, AIM-TD, ARM-TD studies. Pride-HD, First-HD, ARC-HD, and Teva CNS>

4:42 PM 007 Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Moderate to Severe Tardive Dyskinesia (TD) Karen E. Anderson
Disclosure:
Dr. Anderson has received personal compensation for activities with LEGATO-HD, AIM-TD, ARM-TD studies. Pride-HD, First-HD, ARC-HD, and Teva CNS>

4:54 PM 008 Safety of OnabotulinumtoxinA Treatment With Concomitant Antithrombotic Therapy in Patients With Post-stroke Spasticity: A Pooled Analysis of Randomized, Double-Blind Studies Rozalina Dimitrova, MD, MPH
Disclosure:
Dr. Dimitrova has received personal compensation for activities with Allergan as an employee. Dr. Dimitrova holds stock and/or stock options in Allergan.

Register Now

Related Courses

Saturday April 21, 2018

7:00 AM-9:00 AM
C4 Hyperkinetic Movement Disorders: Videodiagnosis and Treatment Steven Frucht MD
9:30 AM-11:30 AM
C14 Parkinson's Disease Update Melissa Nirenberg MD, PhD, FAAN
1:30 PM-3:30 PM
C23 Diagnosis and Treatment of Functional Movement Disorders Mark Hallett MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C24 Hot Topics and Controversies in Parkinson's Disease Melissa Nirenberg MD, PhD, FAAN
1:00 PM-3:00 PM
C36 Nonmotor Manifestations of Parkinson's Disease I Charles Adler MD, PhD, FAAN
3:30 PM-5:30 PM
C50 Nonmotor Manifestations of Parkinson's Disease II Charles Adler MD, PhD, FAAN

Monday April 23, 2018

7:00 AM-9:00 AM
C65 Video EEG: Name That Spell Amy Crepeau MD
C58 Balance and Gait Disorders Bastiaan Bloem MD, PhD
1:00 PM-3:00 PM
C67 Evaluating Tremor in the Office Vicki Shanker MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C139 Paroxysmal Movement Disorders Kailash Bhatia MD, FAAN
1:00 PM-5:30 PM
C158 Clinical Uses of Botulinum Toxin for Dystonia Skills Workshop Diego Torres-Russotto MD, FAAN

Thursday April 26, 2018

7:00 AM-9:00 AM
C176 The Dystonia: Diagnosis, Treatment and Update on Etiologies Rachel Saunders-Pullman MD
1:00 PM-3:00 PM
C186 Cerebellar and Afferent Ataxias: Diagnosis and Management Massimo Pandolfo MD, FAAN
3:30 PM-5:30 PM
C208 Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop Allison Brashear MD, MBA, FAAN
6:30 PM-9:30 PM
C212 Case Studies: Unusual Movement Disorders Kailash Bhatia MD, FAAN

MEMBER LOG IN

Forgot Password?